In a collaboration with Istituto Superiore di Sanità and CNR, IRBM has published research that identified new molecules which block the transmission of the malaria parasite from an infected person to the mosquito, the first step in developing new drugs to eliminate this major infectious disease.
19th November 2018, Pomezia, Italy – IRBM, a global contract research organization (CRO), has strengthened its position in neurodegenerative disease research following an extension of its long-standing collaboration with CHDI Foundation, a nonprofit biomedical research organization exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease (HD).
HD is a genetic neurodegenerative disease for which there are currently only very limited treatment options. The collaboration with CHDI demonstrates IRBM’s commitment and passion for developing novel therapeutic solutions for this devastating disease.
Since 2011, IRBM has worked closely with CHDI to investigate innovative therapeutic approaches based on a better understanding of the biology of the disease. This has included significant contributions by IRBM to HD-specific mechanistic and translational research, as well as tailored drug discovery solutions.
The extension of this collaboration builds on IRBM’s expertise in the biology of neurodegenerative diseases, its comprehensive screening capabilities and continued access to IRBM’s compound collection and peptide libraries. IRBM will also continue to leverage its significant experience in integrated neuroscience drug discovery with small molecules and biologics, including the development of clinically qualified diagnostic assays and the creation of predictive models for blood-brain barrier permeability.
Piero Di Lorenzo, President and Founder of IRBM, said: “We are proud to be involved with this world-leading initiative to improve the quality of life of patients fighting against this terrible disease. Together with CHDI we are fully committed to help them: they deserve nothing less than our daily dedication.”
Robi Blumenstein, President of CHDI Management, Inc., said: “We are delighted to extend CHDI’s collaboration with our colleagues at IRBM. They have made invaluable contributions to a number of our programs and offer important services to the entire HD drug development community.”
Notes to the Editor
For further information, images and interview opportunities with IRBM, please contact:
Pranika Sivakumar, Notch Communications
+44 (0) 161 457 7230
IRBM is a Contract Research Organization with expertise in advancing integrated drug discovery projects, having delivered 25 preclinical candidates and four drugs that are currently on the market. With all their world-class facilities on one site, fully integrated programs are executed under one roof. IRBM works with pharmaceutical companies, non-profit organizations and academic institutions, to quickly and efficiently advance their projects through the drug discovery and development pipeline.
For more information, please visit: www.irbm.com
About CHDI Foundation, Inc.
CHDI Foundation, Inc. is a privately-funded nonprofit biomedical research organization that is exclusively dedicated to collaboratively developing therapeutics that substantially improve the lives of those affected by Huntington’s disease. As a collaborative enabler CHDI seeks to bring the right partners together to identify and address critical scientific issues and move drug candidates to clinical evaluation as quickly as possible. Our scientists work closely with a network of more than 700 researchers in academic and industrial laboratories around the world in the pursuit of these novel therapies, providing strategic scientific direction to ensure that our common goals remain in focus. More information about CHDI can be found at www.chdifoundation.org.